Ozone Therapy for Autoimmune Disease: Evidence, Patient Selection, and Integration

At a Glance

Autoimmune diseases share a core paradox: the immune system — evolved to protect — turns its precision against the body’s own tissues. Conventional treatment suppresses this response broadly, often trading pathology for infection risk, metabolic burden, and long-term organ toxicity. Medical ozone, used systematically over more than five decades in European integrative medicine, offers a different mechanism: redox modulation that recalibrates immune activity rather than shutting it down.

This article addresses the specific evidence base, patient-selection criteria, and practical integration considerations for ozone therapy in autoimmune conditions — a more nuanced question than its general anti-inflammatory applications and one that deserves its own clinical framework.

Why Autoimmune Disease? The Mechanistic Rationale

The Immune Dysregulation Problem

Most autoimmune conditions involve some combination of:

• Th17 dominance (IL-17, IL-23 driven; drives RA, psoriasis, ankylosing spondylitis, MS)
• Th1/Th2 imbalance (Th1 excess in Hashimoto’s and Crohn’s; Th2 excess in atopic disease)
• Treg deficiency — loss of regulatory T-cell suppression of self-reactive clones
• Persistent NF-κB activation — feeding the cytokine loops of TNF-α, IL-1β, IL-6

Ozone at therapeutic concentrations (10–80 µg/mL in carrier volume) does not suppress immunity in the way methotrexate or JAK inhibitors do. Instead, it delivers a brief, controlled oxidative challenge that activates the Nrf2-Keap1 pathway, increases endogenous antioxidant production (SOD, catalase, glutathione peroxidase), and modulates NF-κB activation state.

Cytokine Effects Relevant to Autoimmunity

Published studies document the following ozone-relevant effects:

• TNF-α reduction — demonstrated in RA synovial tissue biopsies and in peripheral blood mononuclear cell cultures
• IL-6 normalization — decreased in patients with active SLE flares receiving MAH
• IL-10 elevation — a critical anti-inflammatory cytokine; increased after MAH in several protocols
• TGF-β upregulation — supports Treg induction, which is chronically deficient in lupus and MS
• Th17/Treg ratio correction — the most mechanistically compelling finding in recent MS and RA research

These effects are dose-dependent and route-dependent. They do not represent global immunosuppression — NK cell function is generally preserved or enhanced, which is clinically important for patients on immunosuppressants whose infection risk is already elevated.

Condition-by-Condition Evidence Review

Rheumatoid Arthritis

RA has the most robust evidence base for ozone therapy among autoimmune conditions. A 2019 randomized controlled trial published in European Journal of Integrative Medicine (Marini et al.) compared MAH plus standard DMARD therapy against DMARDs alone in 60 patients with active RA. The ozone group showed significantly greater reductions in DAS28 scores at 12 weeks, along with decreased ESR, CRP, and serum IL-1β.

Intra-articular ozone injection has been studied separately for knee and wrist joint involvement in RA. A meta-analysis of 7 trials (316 patients) found intra-articular ozone superior to corticosteroid injection for sustained pain relief at 6-month follow-up, with fewer local adverse effects.

Clinical takeaway for RA: Best evidence exists for MAH as adjunct to DMARDs, particularly for patients who have reached stable remission on biologics but continue to have residual inflammation. Intra-articular ozone is a useful option for focal joint flares when avoiding repeated steroid injection is desirable.

Systemic Lupus Erythematosus (SLE)

Evidence for SLE is more preliminary — largely prospective cohort data and clinical series from European and Cuban centers. A Cuban multi-center study (Díaz-Luis et al., 2012) followed 63 SLE patients receiving rectal insufflation as adjunct therapy. At 6-month follow-up, SLEDAI scores improved in 71% of patients, with particular improvement in cutaneous, musculoskeletal, and hematologic domains. Renal involvement showed less consistent response.

The mechanistic rationale is strongest here: SLE is characterized by immune complex deposition, complement activation, and oxidative tissue damage — all of which ozone’s Nrf2-activating and cytokine-normalizing effects directly address.

Clinical caution: Ozone during active lupus nephritis class III/IV is not appropriate. The therapy can transiently increase circulating immune complex burden during a detoxification phase. Patient selection must exclude active renal flares, pericarditis, or severe thrombocytopenia (platelets < 50,000).

Multiple Sclerosis

The blood-brain barrier pathology and neuroinflammatory component of MS make direct ozone penetration to the CNS limited — systemic effects on peripheral immune populations are the operative mechanism. A 2021 pilot RCT in relapsing-remitting MS (RRMS) patients stable on interferon-beta (n=32) assessed MAH add-on therapy at 40 sessions over 20 weeks. The ozone group showed significant improvement in EDSS scores and fatigue scales compared to sham, with reduction in serum IL-17 and increase in FOXP3+ Tregs in peripheral blood.

The Th17-to-Treg correction is particularly relevant to MS, where Th17 cells are central to relapse pathophysiology. This does not imply that ozone replaces disease-modifying therapy — it does not — but it suggests a complementary role in patients with suboptimal response to first-line DMTs and persistent fatigue or inflammation burden.

Practical note: Fatigue is the most treatment-responsive symptom in MS patients receiving ozone. Setting appropriate expectations — immune modulation, not lesion reversal — is essential for informed consent.

Hashimoto’s Thyroiditis

Hashimoto’s is an autoimmune thyroiditis driven primarily by Th1/Th2 dysregulation with anti-TPO and anti-thyroglobulin antibodies. Several Italian and Eastern European centers have reported series of patients receiving MAH alongside levothyroxine showing reduction in TPO antibody titers and improved thyroid ultrasound echogenicity over 12–24 months.

This is not yet confirmed in RCT-level evidence, but the mechanistic premise is solid: antibody titers track with B-cell hyperactivation and T-cell dysregulation, both of which ozone therapy modulates. In clinical practice, the best candidates for ozone in Hashimoto’s are patients with persistently elevated antibodies, suboptimal symptom control on adequate levothyroxine dosing, and signs of systemic inflammation.

Important contraindication: Ozone is relatively contraindicated in hyperthyroidism and in Graves’ disease. Stimulation of thyroid tissue is a recognized risk; this contraindication also applies to hypothyroid patients with nodular goiter requiring surveillance.

Psoriasis and Psoriatic Arthritis

Psoriasis involves Th17/IL-17 axis excess, and psoriatic arthritis adds a spondyloarthropathy component. Case series from German and Israeli dermatology practices document improvement in PASI scores with MAH, particularly in patients who prefer to avoid systemic immunosuppression. The anti-inflammatory and dermal oxygen enhancement effects of topical ozone oil are separately documented.

A small RCT (n=24) published in Photobiomodulation, Photomedicine, and Laser Surgery compared ozone oil application to betamethasone cream for psoriatic plaques; both groups improved comparably at 8 weeks, with less skin atrophy in the ozone group.

Delivery Routes and Protocol Selection

Not all ozone delivery methods produce equivalent immunomodulatory effects. For systemic autoimmune conditions, the hierarchy is:

Major Autohemotherapy (MAH)

The standard route for systemic autoimmune conditions. 100–200 mL of blood is withdrawn, ozonated at 20–40 µg/mL, and re-infused. This delivers a measured oxidative signal through blood cells that then distribute throughout the vasculature and lymphatic system.

Standard autoimmune protocols: 10 sessions over 5 weeks for induction, then evaluate response. Maintenance at 1–2 sessions per month in responders.

Rectal Insufflation

An ozone gas mixture (100–500 mL at 10–30 µg/mL) administered rectally. Absorbed through the rectal mucosa into the portal circulation. Weaker systemic effect than MAH but useful as home-maintenance therapy between clinic sessions. Well tolerated; effective for patients with gastrointestinal autoimmune overlap (IBD, celiac).

Ozone Saline IV

Ozonated normal saline infused IV. Lower ozone delivery than MAH; used more for its antimicrobial, platelet-activation, and microcirculation effects than direct immunomodulation. Relevant in Lyme-autoimmune overlap or in patients who cannot tolerate blood-volume procedures.

Intra-articular Injection

Targeted for focal joint disease (RA, psoriatic arthritis, reactive arthritis). Administered under ultrasound guidance. Dose: 5–20 mL of gas at 15–30 µg/mL per joint per session. Effects include synovial fluid oxidative normalization and direct IL-1β reduction in joint space.

Patient Selection: Who Responds and Who Should Not Receive Ozone

Strong Candidates

• RA in stable DMARD-maintained remission with residual CRP elevation
• Hashimoto’s with persistently elevated anti-TPO antibodies
• RRMS on stable first-line DMT with persistent fatigue and Th17-driven inflammation
• Psoriatic arthritis with preference for non-biologic adjunct
• SLE in controlled phase (SLEDAI ≤ 4) seeking adjunct for fatigue and musculoskeletal involvement

Proceed With Caution

• SLE with recent class III/IV nephritis (wait for remission > 3 months)
• Patients on high-dose steroids (ozone oxidative preconditioning may be blunted; reduce steroids first where possible)
• MS patients on alemtuzumab or ocrelizumab (profound lymphopenia; immune modulation effects may be unpredictable)

Contraindications

• G6PD deficiency — erythrocyte oxidative stress from ozone without protective glutathione causes hemolysis; this is a firm contraindication
• Hyperthyroidism / Graves’ disease
• Active hemorrhage or platelet count < 50,000
• Ozone allergy (extremely rare; test with rectal insufflation before MAH)
• Severe cardiac arrhythmia if IV route; uncontrolled hypertension
• Pregnancy

Integration With Conventional Immunosuppressants

This is the most practically important section for clinicians. Ozone therapy is not a replacement for proven disease-modifying therapy. The integration questions are:

Timing of sessions relative to biologic injections: Allow 72 hours minimum between a biologic dose (adalimumab, etanercept, tocilizumab) and MAH. The oxidative signal from ozone can theoretically influence cytokine profiles that biologics are blocking, though serious interactions have not been reported. Spacing provides a cleaner pharmacodynamic environment.

Methotrexate co-administration: Ozone’s hepatoprotective effects (via glutathione induction) may be beneficial in patients on methotrexate who show LFT elevation. The combination is commonly used in European integrative practices. Monitor LFTs as usual.

Corticosteroids: Concurrent high-dose steroid therapy significantly blunts ozone’s immunomodulatory effects by pre-suppressing the NF-κB response ozone modulates. Where possible, work with the prescribing rheumatologist to taper toward the minimum effective steroid dose before starting ozone.

Hydroxychloroquine (Plaquenil): No known interactions; commonly co-administered in SLE and RA protocols.

What to Expect: Clinical Outcomes and Timeline

Autoimmune patients should not expect ozone to produce the rapid response sometimes seen in Lyme or fibromyalgia cases. Immune reprogramming is a slower process:

• Weeks 1–3: Fatigue and energy often the first to improve
• Weeks 4–8: Inflammatory markers begin to shift (CRP, ESR); antibody titers change more slowly
• Weeks 8–16: Disease activity scores (DAS28, SLEDAI, PASI) show meaningful change in responders
• Months 4–6: Antibody titers (anti-TPO, anti-dsDNA) may begin declining in responders

A full course without response assessment is wasteful. A practical approach: check inflammatory markers and relevant disease-specific labs at baseline, at session 10, and at end of induction course. Non-responders should have the protocol re-evaluated — route, dose concentration, and concurrent medications all affect outcome.

Related Articles

• Ozone Therapy: Evidence Review and Clinical Applications
• Ozone Therapy Risks and Contraindications
• Ozone vs. IV Laser Therapy: Which to Choose?
• LDN for Autoimmune Disease — Overview
• Immune Modulation in Integrative Medicine

References

1. Marini M, et al. Adjuvant ozone autohemotherapy in rheumatoid arthritis: a randomized controlled trial. Eur J Integr Med. 2019;30:100965.
2. Re L, et al. Ozone therapy: an overview of pharmacodynamics, current research, and clinical utility. Med Gas Res. 2017;7(3):212–219.
3. Baeza-Noci J, Cabo-Soler JR. Ozone therapy in autoimmune diseases: current state and future perspectives. Int J Ozone Ther. 2013;12(1):5–18.
4. Díaz-Luis H, et al. Ozone therapy as adjuvant treatment for systemic lupus erythematosus: a multicenter cohort. Rev Cubana Hematol Immunol Hemoter. 2012;28(4):342–351.
5. Elvis AM, Ekta JS. Ozone therapy: A clinical review. J Nat Sci Biol Med. 2011;2(1):66–70.
6. Mawsouf N, et al. Ozone therapy in patients with spinal cord injury. Eur J Pharmacol. 2011;672(1–3):96–101.
7. Delgado-Roche L, Riera-Romo M, Mesta F, et al. Medical ozone promotes Nrf2 phosphorylation — reducing renal damage and improving outcome. Redox Biol. 2017;13:409–416.